Quarterly results round-up: Grifols and Masimo grow but more woe for Tengion
This article was originally published in Clinica
Spanish biosciences group Grifols saw its top line grow 30% during its first fiscal half, to €635.3m ($913.3m), boosted by its acquisition of US blood products company Talecris Biotherapeutics. Revenues from Talecris were included in Grifols’ figures from June, and helped increase sales in its bioscience division by 37% to €521.5m. Diagnostics sales were up 4% to €56.8m, and hospital revenues grew 9% to €49.3m.